Amikacin adverse reactions: Difference between revisions
Gerald Chi (talk | contribs) Created page with "__NOTOC__ {{Amikacin}} {{CMG}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = AMIKACIN SULFATE INJECTION [TEVA PARENTERAL MEDICINES, INC.] | ur..." |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Adverse Reactions== | |||
All aminoglycosides have the potential to induce auditory, vestibular and renal toxicity and neuromuscular blockade (see WARNINGS box). They occur more frequently in patients with present or past history of renal impairment, of treatment with other ototoxic or nephrotoxic drugs and in patients treated for longer periods and/or with higher doses than recommended. | |||
=====Neurotoxicity-Ototoxicity===== | |||
Toxic effects on the eighth cranial nerve can result in hearing loss, loss of balance, or both. Amikacin primarily affects auditory function. Cochlear damage includes high frequency deafness and usually occurs before clinical hearing loss can be detected. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = AMIKACIN SULFATE INJECTION [TEVA PARENTERAL MEDICINES, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6ec3129b-c53b-4bdb-913d-a2d0060fa140#nlm34089-3 | publisher = | date = | accessdate = }}</ref> | =====Neurotoxicity-Neuromuscular Blockade===== | ||
Acute muscular paralysis and apnea can occur following treatment with aminoglycoside drugs. | |||
=====Nephrotoxicity===== | |||
Elevation of serum [[creatinine]], [[albuminuria]], presence of red and white cells, casts, [[azotemia]], and [[oliguria]] have been reported. Renal function changes are usually reversible when the drug is discontinued. As would be expected with any aminoglycoside, reports of toxic nephropathy and acute renal failure have been received during postmarketing surveillance. | |||
=====Other===== | |||
In addition to those described above, other adverse reactions which have been reported on rare occasions are skin rash, drug fever, headache, paresthesia, tremor, nausea and vomiting, eosinophilia, arthralgia, anemia, hypotension and hypomagnesemia. Macular infarction sometimes leading to permanent loss of vision has been reported following intravitreous administration (injection into the eye) of amikacin.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = AMIKACIN SULFATE INJECTION [TEVA PARENTERAL MEDICINES, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6ec3129b-c53b-4bdb-913d-a2d0060fa140#nlm34089-3 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 01:56, 31 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Adverse Reactions
All aminoglycosides have the potential to induce auditory, vestibular and renal toxicity and neuromuscular blockade (see WARNINGS box). They occur more frequently in patients with present or past history of renal impairment, of treatment with other ototoxic or nephrotoxic drugs and in patients treated for longer periods and/or with higher doses than recommended.
Neurotoxicity-Ototoxicity
Toxic effects on the eighth cranial nerve can result in hearing loss, loss of balance, or both. Amikacin primarily affects auditory function. Cochlear damage includes high frequency deafness and usually occurs before clinical hearing loss can be detected.
Neurotoxicity-Neuromuscular Blockade
Acute muscular paralysis and apnea can occur following treatment with aminoglycoside drugs.
Nephrotoxicity
Elevation of serum creatinine, albuminuria, presence of red and white cells, casts, azotemia, and oliguria have been reported. Renal function changes are usually reversible when the drug is discontinued. As would be expected with any aminoglycoside, reports of toxic nephropathy and acute renal failure have been received during postmarketing surveillance.
Other
In addition to those described above, other adverse reactions which have been reported on rare occasions are skin rash, drug fever, headache, paresthesia, tremor, nausea and vomiting, eosinophilia, arthralgia, anemia, hypotension and hypomagnesemia. Macular infarction sometimes leading to permanent loss of vision has been reported following intravitreous administration (injection into the eye) of amikacin.[1]
References
Adapted from the FDA Package Insert.